Dr. van den Brink is internationally renowned for his work in the field of bone marrow transplantation, the gut microbiome, and immunotherapy at New York’s MSK, where he is Head of the Division of Hematologic Malignancies. He is also a professor of Medicine and Immunology at Weill Cornell Medical College and holds a joint appointment in the Immunology and Transplantation Program of the Sloan Kettering Institute. At MSK, the van den Brink lab studies novel strategies to improve immune therapies for cancer patients with a special emphasis on the role of the intestinal microbiome in (patho)physiology and therapy, Chimeric Antigen Receptor T-cell therapy, and regeneration of thymic function to improve T-cell immunity. Dr. van den Brink is Co-Director of the Parker Institute for Cancer Immunotherapy at MSK and Medical Council Chairman for DKMS, an international nonprofit organization devoted to bone marrow donor registration. He has received prestigious prizes and honors including the 2022 E. Donnall Thomas Award from the American Society for Transplantation and Cellular Therapy (ASTCT).
Chiara Bonini's main research focus is the development, preclinical and clinical validation of T-cell based gene therapy approaches to treat cancer and she initiated the use of suicide gene therapy applied to allogeneic stem cell transplantation (allo-HSCT). Her lab is currently focused on cancer immunotherapy, genetic manipulation of T cells, including TCR/CAR gene transfer and TCR gene editing. She has been a member of the Boards of ESGCT and ASGCT and chair of the EBMT CTIWP. She is currently member of the ASH Awards and Global Research Award Committees, of the Board of ESH, member of the EHA Subcommittee on Cellular Therapy, Councelor of the Board of EHA and Member of ASGCT Program Committee.
Todd A Fehniger, MD, PhD, is an internationally recognized expert in natural killer (NK) cell biology and therapeutics with more than 25 years of experience. As a physician-scientist, his laboratory program has advance novel basic, translational, and early phase clinical research concepts related to NK cells and innate lymphoid cells. Contributions to the field include discovery of human memory-like NK cells and their translation to the clinic. His clinical practice is focused on patients with lymphoma, leukemia and related blood cancers, including use of cellular therapies and hematopoietic cell transplantation. He is the co-leader of the Siteman Cancer Center Hematopoietic Development and Malignancy Program and Laboratory Director of the Washington University Center for Gene and Cellular Immunotherapy. He also serves as Director of the Siteman Cancer Center Biological Therapy Academic GMP Facility that provides investigational cellular therapy including T, NK, and manipulated hematopoietic cell grafts.
Georg Holländer, MA (Oxon), MD, FMedSci, FRCPCH, FMH Paediatrics (CH), is an internationally recognized expert in developmental immunology with a specific interest in thymic biology. His research group at Oxford University has developed unique mouse models to understand the development and function of the thymus and explore ways to control it. A pediatrician and an immunologist by training, Georg Holländer is a professor in several prestigious universities: the University of Basel and the ETH Zurich in Switzerland, and the University of Oxford in the United Kingdom. Prof. Holländer is also the director of the Botnar Research Center for Child Health in Basel.
Jerome Ritz, MD, is Professor of Medicine at Harvard Medical School and a leading specialist in graft versus leukemia (GVL), graft versus host disease (GVHD), bone marrow transplantation, immuno-oncology and cell manufacturing. Dr. Ritz’s research lab at the Dana-Farber Cancer Institute has revealed mechanisms of GVL and demonstrated the key role of Treg in chronic GVHD after hematopoietic stem celltransplantation. Dr. Ritz is also the Executive Director of the Cell Manipulation Core Facility at the Dana-Farber Cancer Institute. This academic GMP cell manufacturing facility provides a variety of cellular products including CAR T-cells, NK cells, genetically modified hematopoietic stem cells and regulatory T-cells for adult and pediatric patients enrolled on early phase clinical trials.